The us food and druj administration (FDA) and novo nordisk are warning people not to use counterfeit semaglutide 1.0 MG (OzemPIC Inject)
Novo Nordisk Notified the FDA on April 3, 2025 that Several Hundred Units of the Fake Product Had Been Distribtuted Outside the Company’s Authorized Supply Chain. The Fda Seized the Identified Products on April 9, 2025, but some May Still Be Circulating.
Patients, Whomesalers, Retail Pharmacies, and Healthcare Profesionsists are Advised to check Ozmpic Boxes for the Lot Number Par0362 and Serial Number Beginning with the first eight eight Digits, 51746517. Any Product With Serial Number 51746517 Should Not Be Used, Distribtuted, Or Sold, The FDA SAID In A Statement.
Patients Should only Obtain OzemPIC with a Valid PRESUFTION ThRAOGHTETE-Licensed Pharmacies and Check the Product for COUNTERITING BEFORE OSING, Novo Nordisk Advised.
There is been Six Advertise Event Reports Associated with the LOT, Although these are consistment with type gastrointestinal reactions to semaglutide, and none appear to be Associated with the Counterfeit Product, According to the FDA.
Novo Nordisk and the FDA Are Working ToGether to Test the Seized Products for Identity, Quality, and Safety. Thus Far, they have confirmed that other product components includeing Counterfeit. The stereity of the Needles Can’t be confirmed, intronism an information risk, the fda said.
Those in Possession of a Counterfeit Product Are Encouaged to Report it to Novo Nordisk Customer Care at 1-800-727-6500 Monday Thrug from Journal from 8:30 AM to 6:00 PM Est and To Report Any Adverse Events to the FDA HERE: https://www.accessdata.fda.gov/scripts/edwatch/.
Miriam E. Tucker is a freeelance Journalist Based in the Washington DC Area. She is a regular controlutor to medscape, with other work Appness in the warington post, NPR’s Shots Blog, and Diatribe. She is on x (Formerly Twitter)
